Mount Sinai Technologies
Discover the various technologies developed by Mount Sinai inventors that are currently helping the patient population.
Therapeutics
Nasal spray for treatment-resistant depression
For patients of treatment-resistant depression and adults with major depressive disorder with acute suicidal ideation or behavior, Janssen’s SPRAVATO® (esketmine) CIII nasal spray received FDA approval in 2019, in conjunction with an oral antidepressant.
Learn morePain treatment for endometriosis
Orilissa® is the first FDA-approved oral regimen that specifically helps to ease the moderate to severe pain that accompanies endometriosis.
Learn moreTherapy for acute hepatic porphyrias
The translational research by Robert J. Desnick, MD, contributed to the development of GIVLAARI®, an RNA interference therapy for acute hepatic porphyrias, with Alnylam Pharmaceuticals.
Learn moreNasal spray influenza treatment
Mount Sinai researchers developed technology that serves as the foundation for a nasal spray to protect against Influenza A and B sub-types.
Learn moreEnzyme replacement therapy for Fabry disease
Fabrazyme, based on technology developed by Mount Sinai researchers, is the first-ever U.S. approved treatment for Fabry disease, an inherited condition caused by genetic variation. Licensed to Sanofi.
Learn moreDiagnostics
COVID-19 antibody test technology
Semi-quantitative SARS-CoV-2 serology test to detect the presence or absence of COVID-19 antibodies.
Learn moreSelf-testing system to prevent blood clots
A self-monitoring test system that allows patients to measure the effects of anticoagulation therapy for blood clotting events.
Learn morePlatelet reactivity system to identify antiplatelet-related bleeding risk
VerifyNowTM is an FDA-approved test that measures and quantitates platelet responsiveness to a variety of antiplatelet medications to improve treatment decisions. VerifyNowTM is manufactured and distributed by Werfen.
Learn moreDiagnostic test for spinal muscular atrophy
Carrier screening tool for the detection of spinal muscular atrophy (SMA) in silent carriers, developed and launched by researchers from the Department of Genetics and Genomic Sciences at the Icahn school of Medicine at Mount Sinai.
Learn moreDevices
Patient-specific 3D printed joint implants
Technology consists of a semi-autonomous surgical robot and customized joint implants, and is the basis for Monogram Orthopedics, a startup launched by Mount Sinai researchers.
Learn moreAnnuloplasty rings to improve tricuspid valve functioning
Annuloplasty ring to provide high-quality valve repair in patients suffering from tricuspid valve disease. Licensed to Medtronic.
Learn moreAnnuloplasty rings to improve mitral valve functioning
Annuloplasty ring to provide higher quality valve repair in patients suffering from mitral valve disease. Licensed to Edwards Lifesciences.
Learn moreExcimer laser technology to treat pigment-loss skin condition
Highly targeted beam of UVB light to treat vitiligo, which is a long-term skin condition characterized by skin patches that have had pigment loss. Licensed to Strata Skin Sciences.
Learn moreSoftware
Platform for improved outcomes of progressive kidney disease
KidneyIntelX™ delivers critical insights to assess the risk of progressive kidney function decline in patients with type 2 diabetes and early-stage chronic kidney disease to optimize outcomes and improve clinical management. Licensed to Renalytix.
Learn moreResilience assessment and treatment methodology for IBD patients
GRITT™ combines a resilience assessment with personalized psychosocial care plans for disease management of Inflammatory Bowel Disease (IBD) patients, validated to significantly improve outcomes and reduce expensive unplanned care. Licensed to Trellus Health.
Learn moreMobile app for IBD symptom tracking and care team communication
HealthPROMISE is a prescribed mobile application that assesses the impact of electronic patient reported outcomes on improving patients’ quality of life. Licensed to Rx.Health.
Learn more